News & Events


	News

	Launch of Chemokit™ The company's first self-medication kit for the treatment and prevention of Oral Mucositis was launched in October 2007. The kit, which contains Sucralfate, is aimed at healing and preventing mouth ulcers for the Oral Mucositis (OM) market. OM is a severe adverse reaction to chemotherapy and radiotherapy, which peels off the oral mucosa, causing unbearable pain and oral dysfunction. Chemokit will be provided to cancer and bone marrow transplant (BMT) patients as part of an overall medical regime. The product enables continuous treatments for cancer and BMT, thereby increasing survival rates.

	Business collaboration with Anadis Maya-Biotech is partnering with Anadis, a publicly traded Australian biotechnology company, to develop an SMS kit for the treatment of Alimentary Mucotosis (AM) — the severe adverse reaction affecting cancer patients undergoing chemotherapy and radiotherapy. AM-Kit™ contains Anadis's hyper-immune bovine colostrums. The colustrums are immunized against specific targets, contain targeted polyclonal antibodies, address intestinal infections, and treat gastro-intestinal (GI) Mucositis caused by chemotherapy. The kit is aimed at providing the first preventive and curative treatment for AM. The project is supported by the bi-national Australian-Israeli Vistec Fund.

A Site by

News